Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
112
datasets available to search
ShareScore release 0.9.0
Dataset results
112 results for “MDR.”
Genomes plasmids MDR B. fragilis ONT sequence read files in fastq format
<p>Supporting data for the manuscript <em>Complete genome assembly of clinical multidrug resistant Bacteroides fragilis isolates enables comprehensive identification of antimicrobial resistance genes and plasmids.</em></p> <p>Oxford Nanopore reads demultiplexed with <a href="https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=2ahUKEwjNjqL5tY7iAhUawMQBHZHfDasQFjAAegQIAhAB&url=https%3A%2F%2Fgithub.com%2Frrwick%2FDeepbinner&usg=AOvVaw0wikvIUagLuFV38CwKZtia">Deepbinner</a> v0.2.0 and base-called (with demultiplexing) using Albacore v2.3.3. Barcodes and adapters were removed with <a href="https://github.com/rrwick/Porechop">Porechop</a> v0.2.4 with the --discard_middle option.</p> <p>Data from each isolate was produced from two runs per isolate. Data for the individual runs are included here. They can easily be concatenated eg with cat. Runs are named TVS_01,. TVS_02, TVS_03 and TVS_04.</p> <p>Fast5 (only demultiplexed with deepbinner and basecalled with albacore) as well as illumina reads and genome assemblies can be found via the NCBI bioproject accessions:</p> <p>Isolates, NCBI bioproject accession no:</p> <p>CCUG4856T, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA525024">PRJNA525024</a></p> <p>BFO17, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA244943">PRJNA244943</a></p> <p>BFO18, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA244944">PRJNA244944</a></p> <p>S01, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA244942">PRJNA244942</a></p> <p>BFO42, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA253771">PRJNA253771</a></p> <p>BFO67, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA254401">PRJNA254401</a></p> <p>BFO85, <a href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA254455">PRJNA254455</a></p> <p> </p> <p><strong>md5sum's (also found in the file md5.md5):</strong></p> <p>135d0570a1e49e25c8fde59f321cca68 BFO17_TVS_03_99377.barcode02_trimmed.fastq.gz<br> 3c6ca800a1f735937c0cffccd263fb82 BFO18_TVS_01_97673.barcode03_trimmed.fastq.gz<br> dc37823950f529d3a859b7a7c514af8c BFO18_TVS_03_99377.barcode03_trimmed.fastq.gz<br> abd707404f9ebbc38652e45ed378ca21 BFO42_TVS_02.barcode10_trimmed.fastq.gz<br> 9761e9ab082e276624c5778dcbeaffd2 BFO42_TVS_04.barcode10_trimmed.fastq.gz<br> ffc27009c0f7fead1af84ce045dbe5f3 BFO67_TVS_02.barcode09_trimmed.fastq.gz<br> 06c363a7feeeb88f9d195b3769b37f2b BFO67_TVS_04.barcode09_trimmed.fastq.gz<br> 5553c95cc98f4b9d4cfb38c4f8f8f037 BFO85_TVS_02.barcode08_trimmed.fastq.gz<br> b1a8013cba7a079cee6d3bdd6cd97ff2 BFO85_TVS_04.barcode08_trimmed.fastq.gz<br> 8169225219a5fb20935d5f0304aa80c5 CCUG4856T_TVS_01_97673.barcode01_trimmed.fastq.gz<br> a509b0ae912a798a91e677795198c1c6 CCUG5846T_TVS_03_99377.barcode01_trimmed.fastq.gz<br> 8a9d2eb8b626a6e87ed267d31aa220e3 S01_TVS_01_97673.barcode04_trimmed.fastq.gz<br> 69e239a17becc25a4f103dfc3bf5886a S01_TVS_03_99377.barcode04_trimmed.fastq.gz</p>
MDR-TB SIT41_MIRU-VNTR genotyping dataset
<p>The table represents spoligo- and 24 loci MIRU-VNTR genotypes of MDR Mycobacterium tuberculosis strains from Bulgaria </p>
Genome assemblies of four MDR B. fragilis isolates using PacBio data - supporting the PhD Thesis
<p>Unicycler and Canu assemblies using PacBio data of four MDR B. fragilis isolates.</p> <p>Data supporting the PhD Thesis <em>Epidemiology and Genomics of antimicrobial resistance in the Bacteroides fragilis group </em>by Thomas Vognbjerg Sydenham, The research unit of Clinical Microbiology, Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark September 2019.</p> <p> </p>
Caregivers and MDR-TB patients: Dataset for the importance of knowledge and behavior on drug resistance tuberculosis
<p>Multidrug-resistant Tuberculosis (MDR-TB) is a type of Tuberculosis (TB) that is resistant to at least one or more of the main anti-TB drugs, namely Rifampin or Isoniazid, so this infection is more difficult to eliminate. Good knowledge and behavior of caregivers and patients can affect the success of treatment because they tend not to be late in taking treatment. In this data note we provide the details of a research database of 228 MDR-TB caregivers and patients underwent treatment from January 2020 to December 2021 in preferred hospital in West Java, Indonesia. The purposes of this publication are to describe the dataset for external researchers who may be interested in making use of it, and to detail the methods used to obtain the dataset to determine the level of knowledge and behavior of MDR-TB caregivers and patients regarding the disease through a validated questionnaire consisted of the knowledge and behavior distributed to respondents via online and offline.</p>
Figure 1 in Tertiary hospital sewage as reservoir of bacteria expressing MDR phenotype in Brazil
Figure 1. Distribution of antibiotic resistance (%) of bacteria isolated in sewage from a tertiary hospital in Ribeirão Preto, São Paulo, Brazil. AMI: Amikacin; AMO: amoxicillin; AMC: amoxicillin clavulanate; AMP: ampicillin; ASB: ampicillin sulbactam; CPM: cefepime; CTX: cefotaxime; CFO: cefoxitin; CAZ:ceftazidime; CRO: ceftriaxone; CLO:chloramphenicol; COL: colistin; CRX: cefuroxime; CIP:ciprofloxacin; CLI: clindamycin; ERI: erythromycin; ERT: ertapenem; GEN: gentamycin; IPM: imipenem; LNZ: linezolid; MER: meropenem; NIT: nitrofurantoin; TZP:piperacillin tazobactam; SXT:trimethoprim-sulfamethoxazole; TCP: teicoplanin; TET:tetracycline; VAN:vancomycin.
Table 1 in Tertiary hospital sewage as reservoir of bacteria expressing MDR phenotype in Brazil
<p><b>Table 1.</b> Antibiotic resistance profile and multiresistant phenotype of bacteria isolated in sewage from a tertiary hospital located in Ribeirão Preto, São Paulo, Brazil.</p><table><tbody><tr><th><b>Sampling point</b></th><th><b>Species</b></th><th><b>Antibiotic resistance profile*</b></th><th><b>Resistance phenotype</b></th></tr></tbody><tbody><tr><th>Ambulatory</th><td><i>Proteus mirabilis</i></td><td>AMO, AMC, AMP, CAZ, ERT, SXT, TET</td><td>MDR</td></tr><tr><th>care</th><td><i>Yersinia enterocolitica</i></td><td>AMO, AMC, AMP, CTX, CFO, SXT</td><td>MDR</td></tr><tr><th></th><td><i>Enterococcus faecalis</i></td><td>CIP, CLI, GEN, SXT, TET, VAN</td><td>MDR</td></tr><tr><th></th><td><i>Escherichia coli</i></td><td>AMO, AMP, CAZ, SXT, TET</td><td>MDR</td></tr><tr><th></th><td><i>Escherichia coli</i></td><td>AMO, AMP</td><td>-</td></tr><tr><th></th><td><i>Klebsiella pneumoniae</i></td><td>AMO, AMP</td><td>-</td></tr><tr><th>Patient wards</th><td><i>Enterobacter cloacae</i> Complex</td><td>AMI, AMP, ASB, CPM, CFO, CAZ, CRO, CRX, CIP, ERT, GEN, IPM, MER, TZP</td><td>MDR</td></tr><tr><th></th><td><i>Klebsiella ozaenae</i></td><td>AMO, AMP, CTX, CFO, CAZ, CIP, ERT, GEN, IPM, MER, SXT, TET</td><td>MDR</td></tr><tr><th></th><td><i>Hafnia alvei</i></td><td>AMO, AMC, AMP, CTX, CFO, CAZ, ERT, GEN, IPM, MER, SXT</td><td>MDR</td></tr><tr><th></th><td><i>Klebsiella ozaenae</i></td><td>AMO, AMC, AMP, CTX, CFO, CAZ, CIP, ERT, IPM, MER, SXT</td><td>MDR</td></tr><tr><th></th><td><i>Escherichia coli</i></td><td>AMO, AMC, AMP, CTX, CAZ, ERT, IPM, MER, TET</td><td>MDR</td></tr><tr><th></th><td><i>Staphylococcus aureus</i></td><td>AMP, CIP, CLI, GEN, SXT, TCP, TET, VAN</td><td>MDR</td></tr><tr><th></th><td><i>Citrobacter youngae</i></td><td>AMO, AMC, AMP, CFO</td><td>MDR</td></tr><tr><th></th><td><i>Klebsiella pneumoniae</i></td><td>AMO, AMC, AMP, SXT</td><td>-</td></tr><tr><th></th><td><i>Enterococcus gallinarum</i></td><td>CLI, SXT, TET, VAN</td><td>-</td></tr><tr><th></th><td><i>Pseudomonas aeruginosa</i></td><td>CAZ, CIP, GEN</td><td>MDR</td></tr><tr><th></th><td><i>Escherichia coli</i></td><td>AMO, AMP</td><td>-</td></tr><tr><th></th><td><i>Pseudomonas aeruginosa</i></td><td>CAZ</td><td>-</td></tr><tr><th>Confluent point</th><td><i>Klebsiella pneumoniae</i></td><td>AMP, ASB, CPM, CFO, CAZ, CRO, CRX, CIP, ERT, GEN, IPM, MER, TZP</td><td>MDR</td></tr><tr><th></th><td><i>Hafnia alvei</i></td><td>AMO, AMC, AMP, CTX, CFO, CAZ, ERT, IPM, MER, SXT</td><td>MDR</td></tr><tr><th></th><td><i>Serratia liquefaciens</i></td><td>AMO, AMP, CTX, CFO, CAZ, ERT, IPM, MER</td><td>MDR</td></tr><tr><th></th><td><i>Pseudomonas aeruginosa</i></td><td>AMI, AMP, ASB, CPM, CFO, CAZ, CRO, CRX</td><td>-</td></tr><tr><th></th><td><i>Klebsiella pneumoniae</i></td><td>AMO, AMP, CTX, SXT, TET</td><td>MDR</td></tr><tr><th></th><td><i>Hafnia alvei</i></td><td>CTX, CAZ, ERT, IPM, MER</td><td>-</td></tr><tr><th></th><td><i>Escherichia coli</i></td><td>CFO, CAZ, TET</td><td>MDR</td></tr><tr><th></th><td><i>Klebsiella pneumoniae</i></td><td>AMO, AMP, CAZ</td><td>-</td></tr><tr><th></th><td><i>Enterococcus faecium</i></td><td>CLI, SXT</td><td>-</td></tr><tr><th></th><td><i>Escherichia coli</i></td><td>AMP</td><td>-</td></tr></tbody></table>
Treatment Shortening of MDR-TB Using Existing and New Drugs
ClinicalTrials.gov study NCT02619994. IPD Sharing: Not stated. Countries: 1. Publications: 2.
TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
ClinicalTrials.gov study NCT00449644. IPD Sharing: Not stated. Countries: 8. Publications: 5.
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
ClinicalTrials.gov study NCT01918397. IPD Sharing: NO. Countries: 2. Publications: 5.
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
ClinicalTrials.gov study NCT01859923. IPD Sharing: YES. Countries: 2. Publications: 1.
TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
ClinicalTrials.gov study NCT00664313. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
ClinicalTrials.gov study NCT02409290. IPD Sharing: YES. Countries: 7. Publications: 38.
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmon
ClinicalTrials.gov study NCT00910871. IPD Sharing: Not stated. Countries: 12. Publications: 2.
Data from: Photothermal-assisted antibacterial application of GO-Ag nanocomposites against clinical isolated MDR E. coli
Open the record for dataset details and reuse information.
Data from: Spatial and seasonal influences on culturable endophytic mycobiota associated with different tissues of Eugenia jambolana Lam. and their antibacterial activity against MDR strains
Background: Present study focuses on diversity and distribution analysis of endophytic fungi associated with different tissues of Eugenia jambolana. The influence of season and geographical location on diversity and distribution of endophytic fungi has been analyzed. Antibacterial activity of isolated fungal species has also been investigated against MDR bacterial strains. Result: A total of 1896 endophytic fungal isolates were obtained from healthy, surface sterilized tissues of leaf, stem and petiole tissues during summer, monsoon and winter season. Out of 24 fungal species isolated, 20 species belong to class Ascomycetes, 2 to Basidiomycetes and 2 to Zygomycetes. Maximum species diversity was in rainy season whereas colonization frequency was in winter. All the diversity indices showed maximum species diversity at site 5 (Yamunanager), rainy among the seasons and leaf among the tissues studied. Aspergillus genus was most frequently isolated. Aspergillus niger and Alternaria alternata were most dominant species. Three way ANOVA results showed that effect of season was highly significant on species diversity in relation to sites and tissues. 60% endophytic fungal extracts showed significant antibacterial activity against one or more than one MDR bacterial strain. Conclusion: Different fungal species were recovered from different sites but the inter-site comparisons were not significant according to Jaccard similarity coefficient. Diversity of such fungal endophytes indicates that Eugenia jambolana plant acts as an ecosystem facilitating survival of many microbes with impressive antibacterial potential.
MDR Corona Ticker for NLP
<p>Dieser Datensatz enthält einen Crawl der Coronaticker des MDR im Original sowie für Natural Language Processing (NLP) normalisiert. Bilder sind nicht enthalten. Zusätzlich werden diverse Text Mining Analysen beispielhaft durchgeführt und als vorberechnete Beispieldaten sowie frei weiterverwendbare Analyseskripte bereitgestellt.</p> <p>Bitbucket: https://bitbucket.org/jtiepmar/mdr-corona-ticker-for-nlp</p>
antimicrobial susceptibility profiles of MDR indicator bacteria
<table> <tbody> <tr> <td> <p>Sixteen antimicrobial agents were tested in the Sensititre™ panel to evaluate the antimicrobial susceptibility of <em>Salmonella</em> Gallinarum CNHJ001, <em>Salmonella</em> Enteritidis 190610_1, <em>Escherichia coli</em> ROH_0034,<em> Staphylococcus aureus</em> ROH_0029. <em>Escherichia coli</em> ATCC25922 was also tested as a susceptible control. The antimicrobial agents used in these experiments were; ciprofloxacin (<strong>CIP</strong>), nalidixic acid (<strong>NAL</strong>), imipenem (<strong>IMI</strong>), colistin (<strong>COL</strong>), ampicillin (<strong>AMP</strong>), tetracycline (<strong>TET</strong>), chloramphenicol (<strong>CHL</strong>), azithromycin (<strong>AZI</strong>), gentamicin (<strong>GEN</strong>), streptomycin (<strong>STR</strong>), amikacin (<strong>AMI</strong>), trimethoprim/sulfamethoxazole (<strong>SXT</strong>), cefotaxime (<strong>FOT</strong>), ceftriaxone (<strong>AXO</strong>), cefoxitin (<strong>FOX</strong>), ceftazidime (<strong>TAZ</strong>).<br> <em>a. </em>R=resistant<em> b. </em>S=susceptible<em> c. </em>I=intermediate.</p> </td> </tr> </tbody> </table> <p> </p>
Figure 3: Distribution of MDR isolates count among total isolates of ESKAPE pathogens
<p><strong>Figure 3: Distribution of MDR isolates count among total isolates of ESKAPE pathogens</strong></p>
DNA Sequencing of MDR TB in Eastern Siberia
ClinicalTrials.gov study NCT02508610. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
ClinicalTrials.gov study NCT07393438. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.